Drugs / Covovax
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05546502 Comparator | Oct 2022 → Dec 2023 | vaccinia | PT Bio Farma | Completed | No outcome recorded |
| Phase 3 | NCT05433285 Comparator | Jun → Aug 2022 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Covovax | “Covovax® COVID-19 vaccine is a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 betacoronavirus” NCT05433285 ↗1“2 doses of Covovax® - administered with 28 days interval (0.5 mL per dose)” NCT05546502 ↗ |
| Modality | Vaccine | “Covovax® - recombinant spike protein Nanoparticle Vaccine” NCT05433285 ↗ |